Wisconsin is currently home to 1261 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283
Recruiting
This is a study evaluating the safety, pharmacokinetics, and efficacy of MK-1084 alone, and MK-1084 plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: MEDICAL COLLEGE OF WISCONSIN-Cancer Center Clinical Trials Office ( Site 0262), Milwaukee, Wisconsin
Conditions: Advanced Solid Tumors
Register for Updates
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
NCT04840602
Recruiting
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin
Conditions: Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Register for Updates
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: Wisconsin Center for Advanced Research, Milwaukee, Wisconsin
Conditions: Crohn's Disease, Obesity or Overweight
Register for Updates
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086
Recruiting
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: Wisconsin Center for Advanced Research, Milwaukee, Wisconsin
Conditions: Ulcerative Colitis, Obesity or Overweight
Register for Updates
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD
NCT06883305
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/22/2025
Locations: Research Site, Cudahy, Wisconsin
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury
NCT06840899
Recruiting
The goal of this feasibility study is to learn whether Cannabidiol (CBD) can improve urinary incontinence and other symptoms in people with recent spinal cord injury (SCI). Participants will take Epidiolex (purified CBD) for 90 days
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of Wisconsin - Madison, Madison, Wisconsin
Conditions: Supra-sacral Spinal Cord Injury, Spinal Cord Injury, Urinary Incontinence
Register for Updates
The RECAP2 Study: Midazolam and Psilocybin
NCT06692192
Recruiting
The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing. Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing. Participants will: * Receive one of four possible combinations of medications * Undergo an MRI * Complete question... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/22/2025
Locations: UW School of Medicine and Public Health, Madison, Wisconsin
Conditions: Psilocybin
Register for Updates
Using FAPI PET/MRI to Evaluate Prostate Cancer
NCT06675357
Recruiting
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Prostate Cancer Metastatic Disease, Prostate Cancers
Register for Updates
Virtual A2 Study for At Risk Children
NCT06643598
Recruiting
The goal of this behavioral-interventional study is to learn if the Abecedarian Approach implemented virtually for children ages 0-5 with a history of Hypoxic Ischaemic Encephalopathy (HIE) and/or premature birth produces the same effects as when administered at in-person facilities.
Gender:
ALL
Ages:
5 years and below
Trial Updated:
07/22/2025
Locations: University of Wisconsin Madison, Madison, Wisconsin
Conditions: Hypoxic Ischaemic Encephalopathy (HIE), Premature Birth, Cerebral Palsy, Neurological Disorder
Register for Updates
Evaluation of a Simple-Prep Controlled Embolic
NCT06453642
Recruiting
The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in the USA, New Zealand, and Canada.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma, Bone Tumor, Embolization, Portal Vein Embolization
Register for Updates
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259
Recruiting
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/22/2025
Locations: Local Institution - 0033, Milwaukee, Wisconsin
Conditions: Multiple Sclerosis, Relapsing-Remitting
Register for Updates
Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP)
NCT06378528
Recruiting
The objectives of this study are to investigate the feasibility, tolerability, and preliminary efficacy of repeated ketamine-assisted psychotherapy sessions in adolescents with severe posttraumatic stress disorder. The study will enroll adolescents with a current diagnosis of posttraumatic stress disorder (PTSD) to complete three intravenous ketamine administrations accompanied by a psychotherapy session over the span of six weeks. All participants will complete an initial set of preparatory ses... Read More
Gender:
ALL
Ages:
Between 15 years and 17 years
Trial Updated:
07/22/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Posttraumatic Stress Disorder
Register for Updates